Abstract:Background: Baicalin is the main bioactive constitute of the dried roots of Scutellaria baicalensis and possesses various biological activities. However, the poor water solubility and low oral bioavailability limit its efficacy. Objective: The present study was conducted to enhance the dissolution and oral bioavailability of baicalin (BA) through a novel mesoporous carbon nanopowder (MCN) drug carrier. Materials and methods: Solid dispersions (SDs) of BA with MCN were prepared using a solvent evaporation method. The physical state of the formulations was investigated using SEM, differential scanning calorimetry (DSC) and powder X-ray diffraction (XRD). The pharmaceutical performance of pure BA, physical mixture (PM) and SDs was evaluated by performing an in-vitro dissolution test. The pharmacokinetic studies were conducted in SD rats and the analysis of the biological samples was performed on an Acquity UPLC-MS system. The intestinal and renal toxicity test of MCN was also evaluated. Results: The drug release profile indicated that the BA dissolution rate from SDs with a BA/MCN ratio of 1:6 greatly increased in comparison with that of the pure crystalline drug. Furthermore, a pharmacokinetic analysis in rats showed that the BA area under the concentration-time curve for SDs of MCN/BA was 1.83 times larger than that of pure BA. In comparison with the pure drug, the MCN-BA system significantly shortened the time to Tmax and generated higher Cmax. There was no intestinal and renal toxicity of MCN. Conclusion: These results indicated that the oral bioavailability of BA was remarkably improved by the MCN carrier. Additionally, intestinal toxicity test showed that MCN produced no toxicity in the gastrointestinal tract. Our results show that MCN-based SDs could be used to enhance the bioavailability of drugs with poor water solubility. Summary: The drug release profile indicated that the BA dissolution rate from SDs with a BA/MCN ratio of 1:6 greatly increased in comparison with that of the pure crystalline drug.Furthermore, a pharmacokinetic analysis in rats showed that the BA area under the concentration-time curve for SDs of MCN/BA was 1.83 times larger than that of pure BA.In comparison with the pure drug, the MCN-BA system significantly shortened the time to Tmax and generated higher CmaxAbbreviations used: BA: baicalin, MCN: mesoporous carbon nanopowder, SDs: solid dispersions, SEM: scanning electron microscopy, DSC: differential scanning calorimetry, XRD: powder X-ray diffraction, HPLC: high-performance liquid chromatography, PM: physical mixture, S.D.: standard deviation, ANOVA: analysis of variance, RSD: relative standard deviation, ESI: electrospray ionization, IS: internal standard, MRM: multiple reaction monitoring.

Solid-state properties, solubility, stability and dissolution behaviour of co-amorphous solid dispersions of baicalin

An Amorphous Solid Dispersion of Baicalin and its Oral Therapeutic Effect on Ulcerative Colitis

Preparation and characterization of baicalin-poly -vinylpyrrolidone coprecipitate

Characterization and Bioavailability Study of Baicalin-mesoporous Carbon Nanopowder Solid Dispersion

Recent Patents on Solid Dispersions Emphasize Promising Benefits in Solubility Enhancement of Poorly Water-soluble Drugs

Effect of amine functionalization of SBA-15 on controlled baicalin drug release

Amorphous Solid Dispersions: Implication of Method of Preparation and Physicochemical Properties of API and Excipients

Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design

SOLUBILITY ENHANCEMENT BY SOLID DISPERSION METHOD: A REVIEW

Ternary solid dispersions of lacidipine: Enhancing dissolution and supersaturation maintenance through strategic formulation optimization

Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes

Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo

Preparation and physicochemical characterizations of tanshinone IIA solid dispersion

On the inherent properties of Soluplus and its application in ibuprofen solid dispersions generated by microwave-quench cooling technology.

The Effect of Carrier Matrix and the Method of Preparing Solid Dispersion on Physical State and Solubility of Ibuprofen

Preparation, Characterization and in Vivo Evaluation of Formulation of Baicalein with Hydroxypropyl-Beta-Cyclodextrin

The Formation Of A Host-Guest Inclusion Complex System Between -Cyclodextrin And Baicalin And Its Dissolution Characteristics

Enhancing solubility and bioavailability of coenzyme Q10: formulation of solid dispersions using Soluplus® as a carrier

Evaluating the effect of the porous and non-porous colloidal silicon dioxide as a stabilizer on amorphous solid dispersion

Characterization and Evaluation in Vivo of Baicalin-Nanocrystals Prepared by an Ultrasonic-Homogenization-fluid Bed Drying Method

Insights into Cocrystallization and Coamorphization Engineering Techniques in the Delivery of Traditional Chinese Medicine: Formation Mechanism, Solid-State Characterization, and Improved Pharmaceutical Properties